As of December 31, 2023, cash, cash equivalents, and restricted cash was $15.6M. CEO John Bencich commented, “2023 marked a significant turning point for Achieve as we accomplished several key milestones, such as repeating successful efficacy and safety outcomes in the second Phase 3 ORCA-3 trial for smoking cessation, positive data from the Phase 2 ORCA-V1 trial for vaping, and significant progress in our discussions with the FDA to further our goal of bringing cytisinicline forward to aid the millions of individuals who are seeking treatment for nicotine dependence. We are appreciative of the strong support and confidence from our stakeholders, including new investors who participated in the recent financing and smoking cessation opinion leaders who share in our enthusiasm for cytisinicline’s potential.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, March 28, 2024
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
- Achieve Life Sciences announces data from cytisinicline ORCA program
- ACHV Upcoming Earnings Report: What to Expect?
